Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Use of Topotecan in Patients With Refractory Acute Leukemia

This study has been completed.
Sponsor:
Collaborators:
Immunex Corporation
SmithKline Beecham
Amgen
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00100477
First received: December 30, 2004
Last updated: September 24, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2001
  Primary Completion Date: January 2001 (Final data collection date for primary outcome measure)